Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Charles Montgomery

Hematology & Oncology Tupelo, MS Medical Doctor

NPI 1437156197 CMS profile 246270

961South Gloster Street, Tupelo, MS 38801

Open in the dashboard

General payments

$5,518

344 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$24,013 paid to institutions, not to them · program years 2019–2021

Through program year 2023, Charles Montgomery of Tupelo, MS is reported in the CMS Open Payments database as having received $5,518 across 344 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $24,013 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 61st percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $741 39
2022 General $1,924 114
2021 General $651 43
2020 General $727 48
2019 General $1,476 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Montgomery
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Charles Montgomery were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Charles Montgomery Hematology & Oncology median Middle half National median
2019 $1,476 $529 $121–$2,516 $163
2020 $727 $339 $82–$2,213 $114
2021 $651 $263 $49–$1,965 $132
2022 $1,924 $416 $103–$2,395 $149
2023 $741 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novartis Pharmaceuticals Corporation $399 30 payments
  2. Amgen Inc. $365 24 payments
  3. AstraZeneca Pharmaceuticals LP $351 18 payments
  4. Merck Sharp & Dohme Corporation $300 22 payments
  5. Pharmacyclics LLC, An AbbVie Company $294 16 payments
  6. Seattle Genetics, Inc. $288 19 payments
  7. E.R. Squibb & Sons, L.L.C. $280 20 payments
  8. Pfizer Inc. $278 22 payments
  9. Lilly USA, LLC $273 12 payments
  10. Incyte Corporation $181 11 payments
  11. Other $2,509 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,482 341 payments
  2. Education $36 3 payments
Products named General payments · program years 2019–2023
  1. IMBRUVICA $259 14 payments
  2. KEYTRUDA $257 19 payments
  3. OPDIVO $252 18 payments
  4. PADCEV $235 15 payments
  5. XGEVA $179 11 payments
  6. Lenvima $174 12 payments
  7. Nplate $162 10 payments
  8. VERZENIO $157 10 payments
  9. TAGRISSO $157 6 payments
  10. KISQALI $151 10 payments
  11. Other $4,708 308 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record